Skip to main content

Theravance Biopharma, Inc.

corporate_fare Company Profile

Theravance Biopharma, Inc.

TBPH·NASDAQ·Life Sciences·CIK 0001583107

Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing medicines. The company leverages its expertise to develop medicines, including the U.S. Food and Drug Administration (FDA) approved YUPELRI (revefenacin) inhalation solution. YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). On March 3, 2026, the company announced that its ampreloxetine Phase 3 clinical study (CYPRESS), which was in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy, did not meet its primary endpoint in the Orthostatic Hypotension Symptom Assessment composite score. Consequently, the ampreloxetine program is being wound down. A Strategic Review Committee, formed in 2024, is accelerating its review of alternatives to maximize shareholder value, working with Lazard, its independent financial advisor. This review includes evaluating a broad range of value-maximizing and tax-efficient alternatives, such as a potential sale of the company. The company will complete additional analyses of the CYPRESS dataset and Phase 3 program to assess if the data warrants further regulatory discussion.

Theravance Biopharma, Inc. (NASDAQ:TBPH) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for TBPH at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Phase 3 Study Fails, Triggers Major Restructuring and Accelerated Strategic Review
  • Theravance Biopharma's Phase 3 Drug Fails, Halts R&D, Cuts 50% of Workforce
  • Theravance Biopharma Highlights Q1 2026 Ampreloxetine Phase 3 Data, Strong YUPELRI Sales, and $175M in Milestones

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$107.46M
Net Income
$105.89M
Diluted EPS
$2.06
Op. Cash Flow
$238.54M
Free Cash Flow
$238.5M
Operating Income
-$3.6M
Cash & Equivalents
$167.81M
Debt / Equity
0.00×
Net Margin
98.5%
Shares Outstanding
51.07M sh
Source: 10-K · filed 2026-03-23 · accession 0001104659-26-033077

No longer listed

TBPH (Theravance Biopharma, Inc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. The filings and coverage below remain available as an archive.

feed TBPH - Filings & News (Page 2)

TBPH
Mar 03, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
9
TBPH
Mar 03, 2026, 8:33 AM EST
Source: Reuters
Importance Score:
9
TBPH
Jan 12, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
9
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets